Gene therapy by transforming growth factor-β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis

Kidney International

Volumn 55, Issue 2, 1999, Pages 465-475

  Isaka, Yoshitaka ^a,b,c   Akagi, Yoshitaka ^a,b,c   Ando, Yutaka ^a,b,c   Tsujie, Michiko ^a,b,c   Sudo, Tetsuo ^a,b,c   Ohno, Noriko ^a,b,c   Border, Wayne A ^a,b,c   Noble, Nancy A ^a,b,c   Kaneda, Yasufumi ^a,b,c   Hori, Masatsugu ^a,b,c   Imai, Enyu ^a,b,c  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c TORAY INDUSTRIES INC   (Japan)

Author keywords

Fibrosis; Glomerulosclerosis; Injury; Renal lesions; TGF ; Thy 1 GN

Indexed keywords

COMPLEMENTARY DNA; FIBRONECTIN; IMMUNOGLOBULIN FC FRAGMENT; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; GROWTH INHIBITION; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032910706     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00275.x     Document Type: Article

References (32)

1. 1. BORDER WA, RUOSLAHTI E: Transforming growth factor-beta in disease: The dark side of tissue repair. J Clin Invest 90:1-7, 1992
2. 2. BORDER WA, NOBLE NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
3. 3. OKUDA S, LANGUINO LR, RUOSLAHTI E, BORDER WA: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis: Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86:453-462, 1990
4. 4. TOMOOKA S, BORDER WA, MARSHALL BC, NOBLE NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42:1462-1469, 1992
5. 5. KAGAMI S, BORDER WA, RUOSLAHTI E, NOBLE NA: Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. Lab Invest 69:68-76, 1993
6. 6. BORDER WA, NOBLE NA, YAMAMOTO T, HARPER JR, YAMAGUCHI YU, PIERSCHBACHER MD, RUOSLAHTI E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360:361-364, 1992
7. 7. YAMAMOTO T, NAKAMURA T, NOBLE NA, RUOSLAHTI E, BORDER WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818, 1993
8. 8. YAMAMOTO T, NOBLE NA, MILLER DE, BORDER WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45:916-927, 1994
9. 9. TERRELL TG, WORKING PK, CHOW CP, GREEN JD: Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits. Int Rev Exp Pathol 34(Part B):43-67, 1993
10. 10. ISAKA Y, FUJIWARA Y, UEDA N, KANEDA Y, KAMADA T, IMAI E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92:2597-2601, 1993
11. 11. KOPP JP, FACTOR VM, MOZES M, NAGY P, SANDERSON N, BOTTINGER EP, KLOTHMAN PE, THORGEIRSSON SS: Transgenic mice with increased plasma levels of TGF-beta1 develop progressive renal disease. Lab Invest 74:991-1003, 1996
12. 12. SANDERSON N, FACTOR V, NAGY P, KOPP P, KONDAIAH P, WAKEFIELD L, ROBERTS AB, SPORN MB, THORGEIRSSON SS: Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92:2572-2576, 1995
13. 13. AKAGI Y, ISAKA Y, ARAI M, KANEKO T, TAKENAKA M, MORIYAMA T, KANEDA Y, ANDO A, ORITA Y, KAMADA T, UEDA N, IMAI E: Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 50:148-155, 1996
14. 14. ISAKA Y, BREES DK, IKEGAYA K, KANEDA Y, IMAI E, NOBLE NA, BORDER WA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 2:418-423, 1996
15. 15. WRANA JL, ATTISANO L, WIESER R, VENTURA F, MASSAGUE J: Mechanism of activation of the TGF-beta receptor. Nature 370:341-347, 1994
16. 16. MASSAGUE J: TGFβ signaling: Receptors, transducers, and mad proteins. Cell 85:947-950, 1996
17. 17. LIN HY, MOUSTAKAS A, KNAUS P, WELLS RG, HENIS YI, LODISH HF: The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor: A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands. J Biol Chem 270:2747-2754, 1995
18. 18. CAPON DJ, CHAMOW SM, MORDENTI J, MARSTERS SA, GREGORY T, MITSUYA H, BYRN RA, LUCAS C, WURM FM, GROOPMAN JE, BRODER S, SMITH DH: Designing CD4 immunoadhesins for AIDS therapy. Nature 337:525-531, 1989
19. 19. LIN HY, WANG XF, NG-EATON E, WEINBERG RA, LODISH HF: Expression cloning of the TGF-beta type II receptor: A functional transmembrane serine/threonine kinase. Cell 68:775-785, 1992
20. 20. ARUFFO A, SEED B: Molecular cloning of two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system. EMBO J 6:3313-3316, 1987
21. 21. NIWA H, YAMAMURA K, MIYAZAKI J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199, 1991
22. 22. PAGANI F, ZAGATO L, VERGANI C, CASARI G, SIDOLI A, BARALLE FE: Tissue-specific splicing pattern of fibronectin messenger RNA precursor during development and aging in rat. J Cell Biol 113:1223-1229, 1991
23. 23. SCHWARZBAUER JE, PATEL RS, FONDA D, HYNES RO: Multiple sites of alternative splicing of the rat fibronectin gene transcript. EMBO J 6:2573-2580, 1987
24. 24. ALONSO J, GOMEZ-CHIARRI M, ORTIZ A, SERON D, CONDOM E, LOPEZ-ARMADA MJ, LARGO R, BARAT A, EGIDO J: Glomerular upregulation of EIIIA and V120 fibronectin isoforms in proliferative immune complex nephritis. Kidney Int 50:908-919, 1996
25. 25. KANEKO T, MORIYAMA T, IMAI E, AKAGI Y, ARAI M, INOUE T, XIA C, NOGUCHI T, KAMADA T, UEDA N: Expression of transmembrane-type protein tyrosine phosphatase mRNA along rat nephron segments. Am J Physiol 268:F1102-F1108, 1995
26. 26. LIU YC, KAWAGISHI M, KAMEDA R, OHASHI H: Characterization of a fusion protein composed of the extracellular domain of c-kit and the Fc region of human IgG expressed in a baculovirus system. Biochem Biophys Res Commun 197:1094-1102, 1993
27. 27. HEIDARAN MA, MAHADEVAN D, LAROCHELLE WJ: Beta PDGFR-IgG chimera demonstrates that human beta PDGFR Ig-like domains 1-3 are sufficient for high affinity PDGF BB binding. FASEB J 9:140-145, 1995
28. 28. BENNETT BD, BENNETT GL, VITANGCOL RV, JEWETT JRS, BURNIER J, HENZEL W, LOWE DG: Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. J Biol Chem 266:23060-23067, 1991
29. 29. PEPPEL K, CRAWFORD D, BEUTLER B: A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174:1483-1489, 1991
30. 30. MARK MR, LOKKER NA, ZIONCHECK TF, LUIS EA, GODOWSKI PJ: Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. J Biol Chem 267:26166-26171, 1992
31. 31. SHARMA K, JIN Y, GUO J, ZIADEH FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530, 1996
32. 32. SHAH M, FOREMAN DM, FERGUSON MW: Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 339:213-214, 1992